4,4-Dimethyl-3-(4-methylsulfonylphenyl)-2-phenyl-2-cyclobuten-1-one | 186819-03-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4,4-Dimethyl-3-(4-methylsulfonylphenyl)-2-phenyl-2-cyclobuten-1-one
• 英文别名: 3-(4-Methanesulfonyl-phenyl)-4,4-dimethyl-2-phenyl-cyclobut-2-enone；4,4-dimethyl-3-(4-methylsulfonylphenyl)-2-phenylcyclobut-2-en-1-one
• CAS: 186819-03-4
• 化学式: C₁₉H₁₈O₃S
• 分子量: 326.416
• InChiKey: HRYWWQCLGHKRLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,4-Dimethyl-3-(4-methylsulfonylphenyl)-2-phenyl-2-cyclobuten-1-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以99%的产率得到4,4-Dimethyl-3-(4-methylsulfonylphenyl)-2-phenyl-2-cyclobuten-1-ol
  参考文献：
  名称：

  Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors

  摘要：

  A series of novel 2,3-diaryl-2-cyclobuten-1-ones have been synthesized and have been evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-I and COX-2. 4,4-Dimethyl-2-phenyl-3- [4-(methylsulfonyl)phenyl]cyclobutenone 22 was found to be highly selective for inhibition of COX-2 and was orally active (ED(50) = 2.4 mg/kg) in the rat paw edema model. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00501-x
• 作为产物：
  描述：

  4-溴茴香硫醚 在 palladium diacetate 2,4,6-三甲基吡啶 、 N-溴代丁二酰亚胺(NBS) 、 三氟甲磺酸酐 、 lithium acetate 、 四丁基氯化铵 、 间氯过氧苯甲酸 、 lithium chloride 作用下， 以 四氯化碳 、 N,N-二甲基甲酰胺 为溶剂， 生成 4,4-Dimethyl-3-(4-methylsulfonylphenyl)-2-phenyl-2-cyclobuten-1-one
  参考文献：
  名称：

  Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors

  摘要：

  A series of novel 2,3-diaryl-2-cyclobuten-1-ones have been synthesized and have been evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-I and COX-2. 4,4-Dimethyl-2-phenyl-3- [4-(methylsulfonyl)phenyl]cyclobutenone 22 was found to be highly selective for inhibition of COX-2 and was orally active (ED(50) = 2.4 mg/kg) in the rat paw edema model. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00501-x

文献信息

• Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
  申请人：Merck Frosst Canada, Inc.

  公开号：US05817700A1

  公开（公告）日：1998-10-06

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  该发明涵盖了化合物I的新颖化合物，可用于治疗环氧合酶-2介导的疾病。 该发明还涵盖了用于治疗环氧合酶-2介导的疾病的某些药物组合，其中包括化合物I。
• Imidazopyrimidine nucleoside analogues with anti-HIV activity
  申请人：——

  公开号：US20020061896A1

  公开（公告）日：2002-05-23

  The present invention accordingly provides imidazopyrimidine nucleoside compounds of formula (I) 1 and a method for the treatment or prophylaxis of viral infections in mammals, including humans, comprising the step of administrating a therapeutically effective amount of said compound of formula (I), salts or esters of said compound, pharmaceutical acceptable derivatives or pharmaceutically acceptable salts or esters thereof. Further embodiments include the use of said nucleosides in the preparation of a medicament for the treatment of viral infections in mammals, a commercial packages and pharmaceutical formulations comprising said nucleosides as a therapeutically effective agents against an HIV infection.

  因此，本发明提供了式 (I) 的咪唑嘧啶核苷化合物 1 以及一种治疗或预防哺乳动物（包括人类）病毒感染的方法，该方法包括施用治疗有效量的所述式（I）化合物、所述化合物的盐或酯、药学上可接受的衍生物或其药学上可接受的盐或酯的步骤。进一步的实施方案包括使用所述核苷制备治疗哺乳动物病毒感染的药物、包含所述核苷的商业包装和药物制剂，作为抗 HIV 感染的治疗有效制剂。
• BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS
  申请人：Merck Frosst Canada & Co.

  公开号：EP0889878B1

  公开（公告）日：2002-09-04
• USE OF THE CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION THERAPY IN NEOPLASIA
  申请人：G.D. Searle LLC

  公开号：EP1140192B1

  公开（公告）日：2006-04-05
• HOMOGENEOUS PASTE AND GEL FORMULATIONS
  申请人：Merial Limited

  公开号：EP2101736A2

  公开（公告）日：2009-09-23